Immunex
Executive Summary
Federal Trade Commission approves agreement with Hoechst to transfer sole marketing rights for granulocyte-macrophage colony stimulating factor back to Immunex March 29. In July, the two companies settled litigation arising from a co-marketing deal for GM-CSF, sold by Hoechst as Prokine and by Immunex as Leukine. On March 31, Immunex reported that it has submitted a PLA for use of Leukine "for prophylaxis and treatment of chemotherapy-induced neutropenia".